|
Phase 1b study of RGX-202-01, a first-in-class oral inhibitor of the SLC6A8/CKB pathway, in combination with FOLFIRI and bevacizumab (BEV) in second-line advanced colorectal cancer (CRC). |
| |
|
Consulting or Advisory Role - Abbvie; Celgene; Eisai; Ipsen; Novartis; Perthera; Valar Labs |
Research Funding - Ipsen; NGM Biopharmaceuticals (Inst) |
Travel, Accommodations, Expenses - Halozyme |
Other Relationship - FibroGen |
| |
|
Research Funding - Bayer (Inst); Pfizer (Inst); PsiOxus Therapeutics (Inst); Rgenix (Inst) |
| |
|
Consulting or Advisory Role - Bayer; GlaxoSmithKline; Incyte; Janssen; Merck; Seagen |
Research Funding - GlaxoSmithKline; Rgenix (Inst); Seagen |
| |
|
Employment - Janssen Research & Development |
Stock and Other Ownership Interests - Johnson and Johnson |
Research Funding - AstraZeneca (Inst); BioMed Valley Discoveries (Inst); Boston Biomedical (Inst); Inovio Pharmaceuticals (Inst); Merck (Inst); Novartis (Inst); Rgenix (Inst); Takeda (Inst) |
| |
|
Stock and Other Ownership Interests - Alexion Pharmaceuticals (I); BMS (I); Pfizer (I) |
Consulting or Advisory Role - Bayer; Novartis |
Research Funding - Advenchen Laboratories (Inst); Ayala Pharmaceuticals (Inst); Bristol-Myers Squibb (Inst); Lilly (Inst); Pyramid Biosciences (Inst); Rgenix (Inst); The Academic GI Cancer Consortium (Inst); TRACON Pharma (Inst) |
| |
|
|
Consulting or Advisory Role - Amgen (Inst); AstraZeneca (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); Curio Science (Inst); EMD Serono (Inst); Evidera (Inst); Exelixis (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Intellisphere (Inst); Janssen (Inst); Jazz Pharmaceuticals (Inst); Lilly (Inst); Mirati Therapeutics (Inst); Molecular Templates (Inst); Novartis (Inst); Novocure (Inst); Pfizer (Inst); Puma Biotechnology (Inst); Regeneron (Inst); Sanofi/Aventis (Inst) |
Research Funding - Aeglea Biotherapeutics (Inst); Agios (Inst); Apollomics (Inst); Arcus Biosciences (Inst); Arrys Therapeutics (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Bayer (Inst); BeiGene (Inst); BIND Therapeutics (Inst); BioNTech (Inst); Blueprint Medicines (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Calithera Biosciences (Inst); Celgene (Inst); Celldex (Inst); Clovis Oncology (Inst); cyteir (Inst); Daiichi Sankyo (Inst); Denovo Biopharma (Inst); Eisai (Inst); Elevation Oncology (Inst); EMD Serono (Inst); Evelo Biosciences (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); GRAIL (Inst); Hutchison MediPharma (Inst); ImClone Systems (Inst); Immunogen (Inst); Incyte (Inst); Ipsen (Inst); Janssen Oncology (Inst); Kronos Bio (Inst); Lilly (Inst); Loxo (Inst); Macrogenics (Inst); MedImmune (Inst); Merck (Inst); Molecular Partners (Inst); Molecular Templates (Inst); Nektar (Inst); Neon Therapeutics (Inst); Novartis (Inst); Novocure (Inst); Oncologie (Inst); Pfizer (Inst); PTC Therapeutics (Inst); PureTech (Inst); Razor Genomics (Inst); Repare Therapeutics (Inst); Rgenix (Inst); Takeda (Inst); Tesaro (Inst); Tizona Therapeutics, Inc. (Inst); Transgene (Inst); University of Texas Southwestern Medical Center - Simmons Cancer Center (Inst); Verastem (Inst) |
Travel, Accommodations, Expenses - AstraZeneca; Genentech; Novartis |
| |
|
|
Stock and Other Ownership Interests - inspirna |
Consulting or Advisory Role - inspirna |
Patents, Royalties, Other Intellectual Property - My University has submitted patents on RGX-202 and RGX-104 |
Travel, Accommodations, Expenses - inspirna (I) |
Other Relationship - inspirna |
| |
|
Employment - Hummingbird; Inspirna |
Leadership - Biogen; Fortress Biotech; Purple Biotech; Verastem |
Stock and Other Ownership Interests - Biogen; Fortress Biotech; Purple Biotech; Verastem |
Consulting or Advisory Role - Fortress Biotech; Lokon Pharma; Nectin; Triphase |
| |
|
|
Stock and Other Ownership Interests - Inspirna |
Consulting or Advisory Role - AVEO; Hummingbird (Inst); Regeneron (Inst); Sanofi (Inst); Spectrum Pharmaceuticals; Verastem |
Expert Testimony - Sanofi (Inst) |
| |
|
|
Stock and Other Ownership Interests - Inspirna |
Patents, Royalties, Other Intellectual Property - Inspirna; NYU School of Medicine |
Travel, Accommodations, Expenses - Inspirna |
| |
|
No Relationships to Disclose |
| |
|
|
| |
|
Stock and Other Ownership Interests - Inspirna |
Consulting or Advisory Role - atai Life Sciences; Inspirna; Neurogastrx; Synlogic |
Travel, Accommodations, Expenses - Inspirna |
| |
|
Employment - Fortress Biotech; Hummingbird; Inspirna; Nectin Therapeutics; OncoTartis |
Stock and Other Ownership Interests - Acadia; Arrowhead Pharmaceuticals; Merck; Merck; MustangBio; Silverback Therapeutics |
| |
|
|
|
Stock and Other Ownership Interests - Inspirna |
Consulting or Advisory Role - Guidepoint Global; PSP investments |
Patents, Royalties, Other Intellectual Property - I am a co-inventor on several Inspirna assigned patent applications. |
| |
|
|
Stock and Other Ownership Interests - Inspirna |
| |
|
|
Stock and Other Ownership Interests - Inspirna |
| |
|
|
|
Stock and Other Ownership Interests - Inspirna |
Patents, Royalties, Other Intellectual Property - Inspirna |
| |
|
Employment - Inspirna; Northern Biologics; Rgenix |
Leadership - Inspirna; Northern Biologics; Rgenix |
Stock and Other Ownership Interests - Inspirna; Northern Biologics; Rgenix; Roche/Genentech; Sectoral Asset Management; Sixty Degree Capital |
Consulting or Advisory Role - Sectoral Asset Management; Sixty Degree Capital |
Research Funding - Inspirna |
Patents, Royalties, Other Intellectual Property - Patents related to the Rgenix compound RGX-104 |
Travel, Accommodations, Expenses - Inspirna; Northern Biologics; Rgenix |
| |
|
|
Consulting or Advisory Role - Amgen; Array BioPharma; Bayer; GlaxoSmithKline; Incyte; Pfizer; Seagen; Taiho Pharmaceutical; Zhuhai DL Biotech |
Speakers' Bureau - Guardant Health |
Research Funding - Amgen (Inst); AstraZeneca (Inst); Novartis (Inst) |